Best of ASCO - 2014 Annual Meeting

 

Welcome

Chemotherapy

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without systemic bevacizumab, for patients with advanced cancer and liver involvement.

Elena Fountzilas

2527

A phase I study to evaluate safety, tolerability, pharmacokinetics and activity of oraxol in patients (pts) with advanced malignancies.

Wen Wee Ma

2526

Early markers of anthracycline сardiotoxicity in treatment of patients with breast cancer.

Liubov Yu Vladimirova

e14506

Efficacy of thalidomide, neurokinin-1 receptor antagonist, and olanzapine in combination with palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) induced by highly emetogenic chemotherapy (HEC): Bayesian network meta-analysis.

Abdullah Alhifany

e14514

Factors affecting the development of irinotecan-associated acute cholinergic syndrome.

Amrita Singh

e14515

First-in-human phase I study of JPH203, L-type amino acids transporter 1 inhibitor, in patients with advanced solid tumors.

Naohiro Okano

2519

Hepatotoxicity of anthracycline chemotherapy in patients with breast cancer.

Nailya Guskova

e14505

In vitro characterization and in vivo efficacy of NEOS-518, a novel isoquinoline embedded amino oxazole, that demonstrates CDK-1,2, 3, and 9 inhibition.

Sara Anne Little

e14509

Investigation of profile-related evidence determining individualized cancer therapy (I-PREDICT) in heavily pre-treated patients: A role for combinatorial precision cancer therapy.

Jason K. Sicklick

2531

Non-tunneling technique of port insertion for chemotherapy infusions in cancer patients: A single centre study.

Akhil Palod

e14507

Outcomes of pegfilgrastim (PFG) administration on the same day vs the day after chemotherapy (CTX) in the prophylaxis of chemotherapy-induced (Febrile) neutropenia (CIN/FN): Systematic review and meta-analysis.

Neda AlRawashdh

e14510

Phase 1/2a study of BAL101553, a novel tumor checkpoint controller (TCC), administered as 48-hour infusion in adult patients with advanced solid tumors.

Markus Joerger

2529

Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with advanced solid tumors.

Juanita Suzanne Lopez

2530

Plinabulin (Plin), a small molecule with anti-cancer activity and a novel mechanism of action (MoA) in docetaxel (Tax)-induced neutropenia: Phase (φ) 2 results from a head-to-head comparison with Pegfilgrastim (Peg).

Douglas W. Blayney

2528

Prevention of chemo-induced cardiotoxicity with ACE inhibitors and angiotensin receptor blockers.

Purva Sharma

e14513

Repurposing the FLT3 inhibitor quizartinib to enhance 5-FU treatment of mouse models of intestinal tumors.

Wallace York Langdon

e14516

Synthesis and preclinical characterization of novel ruthenium (II) arene complexes for the treatment of solid tumors.

Veronica Corrales-Sanchez

e14512

Toxicity of high-dose chemotherapy in patients with osteosarcoma.

Nailya Guskova

e14508